<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189566</url>
  </required_header>
  <id_info>
    <org_study_id>CAR\TAXHY</org_study_id>
    <nct_id>NCT00189566</nct_id>
  </id_info>
  <brief_title>Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse</brief_title>
  <official_title>National, Randomized, Phase II Study Comparing Efficacy of Weekly Administration of Paclitaxel in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <brief_summary>
    <textblock>
      This study will look at the efficacy and safety of weekly administration of paclitaxel&#xD;
      (Taxol®) in monotherapy compared to paclitaxel in combination with topotecan or carboplatin&#xD;
      in patients with ovarian cancer in early relapse.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this research study is to find out if treatment of early relapse of&#xD;
      ovarian or fallopian tube or peritoneal cancer with paclitaxel (Taxol*) weekly administered,&#xD;
      in lower doses in combination with topotecan (Hycamtin*) or carboplatin will improve efficacy&#xD;
      compared to weekly administration of paclitaxel in monotherapy. Tolerance in the three groups&#xD;
      will be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival of patients in the three groups</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of response and rate of progression at the end of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative and quantitative toxicities</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Malignant Tumor of Peritoneum</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged &gt; 18&#xD;
&#xD;
          -  Histologically proven diagnosis of cancer of the ovary, the fallopian tube or&#xD;
             peritoneum&#xD;
&#xD;
          -  Peritoneal and/or nodes and/or visceral metastases&#xD;
&#xD;
          -  Disease in progression under treatment or within 6 months after a first or second&#xD;
             platinum-based line&#xD;
&#xD;
          -  A period of 3 weeks between last chemotherapy and inclusion&#xD;
&#xD;
          -  Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] criteria) or&#xD;
             cancer antigen (CA) 125 assessable disease (Gynecologic Cancer Intergroup [GCIG]&#xD;
             criteria)&#xD;
&#xD;
          -  ECOG performance status &lt; 2&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously received weekly administration of paclitaxel chemotherapy&#xD;
&#xD;
          -  Involved in a trial within the last 30 days&#xD;
&#xD;
          -  Previously received a bone marrow autogreffe or irradiation of the abdomen within 5&#xD;
             years, due to intensive chemotherapy&#xD;
&#xD;
          -  Prior diagnosis of malignancy&#xD;
&#xD;
          -  History of ischemic cardiopathy, congestive heart failure (New York Heart Association&#xD;
             [NYHA] &gt; 2), arrhythmia, hypertension, or significant valvulopathy&#xD;
&#xD;
          -  Pre-existing motor or sensory neurologic pathology or symptoms National Cancer&#xD;
             Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) grade &gt; 2&#xD;
&#xD;
          -  Bone marrow, renal, or hepatic insufficiency&#xD;
&#xD;
          -  Severe active infection or occlusive or sub-occlusive disease&#xD;
&#xD;
          -  History of symptomatic brain metastases&#xD;
&#xD;
          -  Fertile women not using adequate contraceptive methods&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Hypersensitivity to compounds chemically related to paclitaxel, topotecan, or&#xD;
             carboplatin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laure Chauvenet, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital Hôtel Dieu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>February 24, 2011</last_update_submitted>
  <last_update_submitted_qc>February 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2011</last_update_posted>
  <keyword>Relapse within 6 months</keyword>
  <keyword>Previously received taxane derivative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

